Pro Test Diagnostics is developing a routine test to monitor and detect illegal use of one’s own stored blood to enhance performance in elite athletes. The ABT™-test can expose athletes who have used blood doping and the result is not affected by the athlete’s training intensity, the use of high-altitude training or the use of low oxygen tents.
Cyanobacteria have significant potential as industrial biotechnology platforms to produce a wide variety of bio-products, such as polymers, sugars and powerful antioxidants such as C-phycocyanin. Our team have created a set of genetic tools that give significant advantages in the microalgae industry for save, efficient and specific bioproduction.
We are developing an oral patch, which will be a patented galenic formulation, providing rapid pain relief for the patient. The product can theoretically reach a target patient population of 10-20,000 patients annually in Sweden, and considerably higher in international markets.
Delayed or inappropriate treatment of anaerobic infections may result in severe disease or death. With knowledge levels dropping in clinical laboratories, the need for anaerobic proficiency increase. Dianox is developing educational solutions to halt this trend in health care.
We are developing a targeted mass-spectrometry biomarker tool for differentiating subgroups of patients with Parkinsonian disorders exhibiting similar clinical symptoms but having distinct molecular etiologies of neurological disease.
Quretech Bio develops innovative antibiotics by stopping bacterial virulence with a first-in-class active substance. The approach is not to kill bacteria, but make them harmless – thus complementing existing treatments and making established antibiotic drugs more effective without causing resistance.
The project aims to develop an antibody that could improve clinical outcomes for a large group of patients with prostate cancer. The approach is an antibody that is expected to have much less side effects than current treatments for this indication.
Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 650 million people living with acne around the world. This case focuses on a novel approach to fighting acne without the hazards of antibiotic resistance development.
Brain stimulation offer digital evidence-based virtual reality rehabilitation for improved quality of life for stroke patients. We offer an accessible treatment strategy for patients suffering from neglect with shorter stay at hospital and eventually less need of support in their daily life.
We have identified a new type of selective yet non-toxic and environmentally-friendly insecticide aimed at mosquitos. Unlike other similar products, this compound does not harm other pollinators and is harmless to humans. By applying our findings we hope to prevent millions of infections yearly.
Current drugs against mycoses are toxic. We aim to develop a new class of antifungal agents that disarm the invasive forms of fungal cells instead of merely eradicating them. This has two advantages: The new compounds are less aggressive for the host and resistance development is reduced.
The aim of this project is to develop a new and unique biological pharmaceutical drug, targeting a central mechanism in chronic inflammation (a monoclonal antibody directed towards the protein bile salt-stimulated lipase, BSSL) as an orphan drug for the more severe forms of Juvenile Idiopathic Arthritis (JIA), providing patients with an effective treatment alternative and with less adverse effects than the drugs used today.
InfiCure Bio offer advanced drug validation services for pharmaceutical companies developing drugs against fibrosis – or scar tissue formation in organs. The shortage of existing model systems that reflect human fibrotic disease conditions, make this a very attractive CRO-service for pharmaceutical developers.
Our project goals aim at increased survival, improved quality of life and less suffering for cancer patients. Our novel chemical entities (NCE) can prevent over-activation of certain signaling pathways and are based on existing pharmaceuticals that are well tolerable and easy to produce. This will be a first in class drug with little side effects (known drug class), addressing cancer induced cachexia and suppression of the immune system.
Hiloprobe AB has developed a superior method of diagnosing and prognosing patients with colorectal cancer after surgery. Their innovative clinical tool – the ColoNode is far more accurate than current standard procedures, opening up the possibility of personalized medicine within the colorectal cancer field.